IMMX Immix Biopharma10.23-1.24 (-10.8%)
IMMX Immix Biopharma8.66-0.28 (-3.1%)
IMMX Immix Biopharma10.58+0.66 (+6.7%)
IMMX Immix Biopharma5.23-0.33 (-5.9%)
IMMX Immix Biopharma2.91+0.15 (+5.4%)
Premarket Decliner
IMMX Immix Biopharma2.90+0.04+1.4%
Premarket:2.25-0.65 (-22.4%)
Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody Tislelizumab
Globe NewswireWed, 3-May 8:00 AM